Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing M Imielinski, AH Berger, PS Hammerman, B Hernandez, TJ Pugh, ... Cell 150 (6), 1107-1120, 2012 | 2023 | 2012 |
Characterizing the cancer genome in lung adenocarcinoma BA Weir, MS Woo, G Getz, S Perner, L Ding, R Beroukhim, WM Lin, ... Nature 450 (7171), 893-898, 2007 | 1287 | 2007 |
Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer PS Hammerman, ML Sos, AH Ramos, C Xu, A Dutt, W Zhou, LE Brace, ... Cancer discovery 1 (1), 78-89, 2011 | 589 | 2011 |
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer A Dutt, AH Ramos, PS Hammerman, C Mermel, J Cho, T Sharifnia, ... PloS one 6 (6), e20351, 2011 | 445 | 2011 |
Induction of COX‐2 by LPS in macrophages is regulated by Tpl2‐dependent CREB activation signals AG Eliopoulos, CD Dumitru, CC Wang, J Cho, PN Tsichlis The EMBO journal, 2002 | 350 | 2002 |
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2 H Greulich, B Kaplan, P Mertins, TH Chen, KE Tanaka, CH Yun, X Zhang, ... Proceedings of the National Academy of Sciences 109 (36), 14476-14481, 2012 | 327 | 2012 |
Tpl2/cot signals activate ERK, JNK, and NF-κB in a cell-type and stimulus-specific manner S Das, J Cho, I Lambertz, MA Kelliher, AG Eliopoulos, K Du, PN Tsichlis Journal of Biological Chemistry 280 (25), 23748-23757, 2005 | 203 | 2005 |
Identification of ROS1 rearrangement in gastric adenocarcinoma J Lee, SE Lee, SY Kang, IG Do, S Lee, SY Ha, J Cho, WK Kang, J Jang, ... Cancer 119 (9), 1627-1635, 2013 | 163 | 2013 |
Cetuximab response of lung cancer–derived EGF receptor mutants is associated with asymmetric dimerization J Cho, L Chen, N Sangji, T Okabe, K Yonesaka, JM Francis, RJ Flavin, ... Cancer research 73 (22), 6770-6779, 2013 | 113 | 2013 |
Amplification of chromosomal segment 4q12 in non-small cell lung cancer AH Ramos, A Dutt, C Mermel, S Perner, J Cho, CJ Lafargue, LA Johnson, ... Cancer biology & therapy 8 (21), 2042-2050, 2009 | 107 | 2009 |
Phosphorylation at Thr-290 regulates Tpl2 binding to NF-κB1/p105 and Tpl2 activation and degradation by lipopolysaccharide J Cho, PN Tsichlis Proceedings of the National Academy of Sciences 102 (7), 2350-2355, 2005 | 82 | 2005 |
Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6 E Park, N Kim, SB Ficarro, Y Zhang, BI Lee, A Cho, K Kim, AKJ Park, ... Nature structural & molecular biology 22 (9), 703-711, 2015 | 79 | 2015 |
Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies J Cho, S Pastorino, Q Zeng, X Xu, W Johnson, S Vandenberg, R Verhaak, ... Cancer research 71 (24), 7587-7596, 2011 | 79 | 2011 |
High expression of microRNA-196a indicates poor prognosis in resected pancreatic neuroendocrine tumor YS Lee, H Kim, HW Kim, JC Lee, KH Paik, J Kang, J Kim, YS Yoon, ... Medicine 94 (50), e2224, 2015 | 73 | 2015 |
Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target H Watanabe, JM Francis, MS Woo, B Etemad, W Lin, DF Fries, S Peng, ... Genes & development 27 (2), 197-210, 2013 | 70 | 2013 |
Tpl2 (tumor progression locus 2) phosphorylation at Thr290 is induced by lipopolysaccharide via an Iκ-B kinase-β-dependent pathway and is required for Tpl2 activation by … J Cho, M Melnick, GP Solidakis, PN Tsichlis Journal of Biological Chemistry 280 (21), 20442-20448, 2005 | 67 | 2005 |
Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification ST Kim, HL Jang, SJ Lee, J Lee, YL Choi, KM Kim, J Cho, SH Park, ... Molecular cancer therapeutics 13 (11), 2527-2536, 2014 | 41 | 2014 |
Integrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumors G Kang, H Yun, CH Sun, I Park, S Lee, J Kwon, I Do, ME Hong, ... Oncotarget 7 (6), 6538, 2016 | 38 | 2016 |
Potentiating therapeutic effects of epidermal growth factor receptor inhibition in triple-negative breast cancer KS You, YW Yi, J Cho, JS Park, YS Seong Pharmaceuticals 14 (6), 589, 2021 | 37 | 2021 |
Dual inhibition of AKT and MEK pathways potentiates the anti-cancer effect of gefitinib in triple-negative breast cancer cells KS You, YW Yi, J Cho, YS Seong Cancers 13 (6), 1205, 2021 | 32 | 2021 |